Carvedilol vs endoscopic band ligation for the prevention of variceal bleeding: a meta-analysis

Shan Tian1,*, Ruixue Li2,*, Yingyun Guo1, Xuemei Jia1, Weiguo Dong1

1Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China; 2Department of Gastroenterology, Renmin Hospital of Macheng City, Macheng, Hubei, People’s Republic of China

*These authors contributed equally to this work

Objective: Variceal hemorrhage is the primary driver of mortality in patients with portal hypertension. Recent guidelines recommended that patients with esophageal varices should receive endoscopic band ligation (EBL) or carvedilol as prophylaxis of variceal bleeding. Several clinical trials have compared carvedilol use with EBL intervention, yielding controversial results. The present study aimed to perform a meta-analysis of randomized controlled trials (RCTs) evaluating the benefits and harms of carvedilol vs EBL for the prevention of variceal bleeding.

Methods: Studies were searched on Pubmed, Embase, Medline, and Cochrane library databases up to August 2018. Main outcomes in selected studies (variceal bleeding, all-cause deaths, bleeding-related deaths, and adverse events) were pooled into a meta-analysis.

Results: Seven RCTs were identified in this meta-analysis, including a total of 703 patients. A total of 359 patients were randomized to carvedilol group and 354 were randomized to EBL group. No significant difference in variceal bleeding was observed between carvedilol use and EBL groups (relative ratio [RR] = 0.86, 95% CI = 0.60–1.23, I² = 11%), without publication bias. No significant difference was found neither for all-cause deaths (RR = 0.82, 95% CI = 0.44–1.53, I² = 66%) nor for bleeding-related deaths (RR = 0.85, 95% CI = 0.39–1.87, I² = 42%) in four included studies. Moreover, no reduced trend was observed toward adverse events in carvedilol group compared with that in EBL group (RR = 1.32, 95% CI = 0.75–2.31, I² = 81%).

Conclusion: There is no significant difference between carvedilol use and EBL intervention for the prophylaxis of variceal bleeding in patient with esophageal varices. Large-scale clinical trials are further needed to make a confirmed conclusion.

Keywords: carvedilol, endoscopic band ligation, variceal bleeding, portal hypertension

Introduction

Variceal hemorrhage is one of the most lethal complications of portal hypertension.1 One-third of patients with esophageal varices will develop gastrointestinal bleed, and the risk of bleeding is correlated with increased high hepatic venous pressure gradient (HVPG).2 Therefore, in order to reduce mortality, it is of great significance to prevent variceal hemorrhage in the clinical management of patients with cirrhosis.

Among several recommended strategies, the most proposed treatment options are non-selective beta-blockers (NSBB) and endoscopic band ligation (EBL).3 In clinical practice, <50% of patients with liver cirrhosis are sensitive to propranolol or nadolol with regard to hemodynamic aspects.4 Carvedilol, a third generation of NSBB, has been shown to possess an additional property of vasodilatation due to its intrinsic anti-α adrenergic activity.5 Carvedilol can effectively reduce cardiac output and splanchnic blood flow, while the action on α1 receptor leads to splanchnic vasoconstriction, decreasing HVPG and the incidence of related complications.6 Studies have demonstrated that carvedilol is superior to the traditional NSBB – propranolol,
in reducing portal pressure. In a meta-analysis based on five high-quality randomized controlled trials (RCTs), the proportion of patients with the use of carvedilol was much higher in achieving a target hemodynamic response (reduction ≥20% of baseline or to ≤12 mmHg) compared with those with propranolol.

Accumulating evidence indicates that endoscopic techniques are the effective intervention to prevent variceal bleeding in patients with severe or moderate varices. Compared with endoscopic injection sclerotherapy, EBL is a purely mechanical method of eradicating varices, with fewer endoscopic sessions and less frequent complications. Recently, several clinical trials have compared the effects of carvedilol with EBL for the primary or secondary prevention of variceal bleeding in patients with portal hypertension. However, the results from these trials were inconsistent. Therefore, we initiated this meta-analysis described here to assess the efficacy and safety of carvedilol use compared with EBL intervention for the prevention of variceal bleeding.

Methods
This protocol was registered on the website of PROSPERO and the registration number was CRD42018106699.

Study eligibility
Inclusion criteria: 1) study design: prospective RCTs; 2) participants: patients with a confirmed diagnosis of esophageal varices by endoscopy; 3) treatment group: carvedilol use; 4) comparison group: EBL intervention; and 5) outcomes: variceal bleeding, all-cause deaths, bleeding-related deaths, and adverse events.

Exclusion criteria: 1) studies that assessed the efficacy of carvedilol without controlled group; 2) retrospective clinical trials, letters to the editor, reviews, and case reports; and 3) studies published in languages other than English.

Search strategy
Pubmed, Embase, Medline, and The Cochrane Library were searched up to August 2018 to identify potential references by two independent investigators (Xuemei Jia and Yingyun Guo). Databases were searched through the following search terms: “carvedilol” AND “endoscopic band ligation”. A manual search of the reference lists of related studies was also conducted by the two investigators. The database search was confined to clinical trials published in English language.

Data extraction and quality assessment
Data from the included studies were extracted by two independent researchers (Shan Tian and Ruixue Li). The following information was extracted from the selected studies: author, year, study period, number of patients, age, sex, presence of ascites, Child–Pugh class, follow-up time, and outcomes. It was decided to resolve any discrepancies through another investigator’s final determination (Weiguo Dong). The guidelines of the Cochrane Handbook of Systematic Reviews of Interventions were applied to evaluate the quality assessment of included studies by the two researchers. The following items were assessed for every selected trial: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. For each item, the risk of bias was evaluated as either low, high, or unclear.

Statistical methods
Relative ratios (RRs) with 95% CIs were applied to calculate with respect to dichotomous data. By using Review Manager software (RevMan, V.5.3, Copenhagen, Denmark, 2014), we performed statistical analysis according to the guidelines of the Cochrane Handbook for Systematic Reviews of Interventions. We calculated the $\chi^2$ and $I^2$ statistics to detect the heterogeneity among included studies. As for $I^2$ statistic, $25%–50%, 50%–75%$, and $>75%$ were separately regarded as low, moderate, and high heterogeneity. Random-effects model was used if substantial heterogeneity across studies was detected; otherwise, a fixed-effects model was adopted. Finally, potential reasons for heterogeneity were probed if significant heterogeneity was found. $P<0.05$ was regarded as statistically significant.

Results
Study identification and selection
Our search identified 58 potential references through database search. A total of 35 reports were excluded due to duplication of publication. A total of 23 studies were considered for further analysis, and one study was added to our meta-analysis through reference lists. One study was a case report and one was a letter to the editor. One high-quality trial evaluated the effect of carvedilol in decreasing portal pressure without controlled group. Besides, 14 references were published as a form of review or meta-analysis. Finally, seven RCTs were included in the quantitative synthesis. The detailed flow diagram of the study selection process is shown in Figure 1.

Description of included studies
Seven prospective RCTs were identified in our meta-analysis, including 713 cases (359 patients in carvedilol...
Therapeutics and Clinical Risk Management 2019:15

Tian et al

58 studies were identified through database search
35 studies were excluded for duplication
23 studies were screened
1 study was included through references
24 studies were assessed for eligibility
Letter/commentary on published trial: 1
No control group: 1; Case report: 1; Review studies: 14
7 studies were included in this meta-analysis

Figure 1 Study selection flow diagram.

Table 1 Clinical features of patients in the included studies

| Author year | Group | Study period | Patients (n) | Age (years) | Men vs women | Ascites (n) | Child–Pugh class | Interventions | Follow-up (months) |
|-------------|-------|--------------|--------------|-------------|--------------|------------|-----------------|---------------|-------------------|
| Elrahim et al, 2018 | C | 2015–5 to 2016–6 | 84 | 51.2±11.0 | 34:66 | 26 | 6.25 mg/d initiation, up to 12.5–50 mg/d EBL/2 weeks until eradication of varices | 12 |
| | EBL | | 88 | 50.6±5.9 | 38:62 | 44 | 20/24/56 |
| Stanley et al, 2014 | C | 2006–6 to 2012–6 | 33 | 51.4±10.8 | 22:11 | 12 | 6.25 mg/d for 1 week, then increased to 12.5 mg/d EBL at 1 week, then 2 weekly | 26.3 |
| | EBL | | 31 | 49.6±12.87 | 21:10 | 12 | 26.3 |
| | | | | | | | (10.2–46.6) |
| Shah et al, 2014 | C | 2007–5 to 2011–9 | 82 | 48.3±1.3 | 59:23 | 33 | 6.25 mg/d initiation then increased to 6.25 mg twice a day EBL/3 weeks until eradication of varices | 13.2±11.7 |
| | EBL | | 86 | 47.2±13.2 | 63:23 | 32 | 13.4±12.4 |
| Tripathi et al, 2009 | C | 2000–4 to 2006–5 | 77 | 54.2±9.4 | 54:23 | 49 | 6.25 mg/d initiation, then increased to 12.5 mg/d EBL/2 weeks until eradication of varices | 26.2±22.1 |
| | EBL | | 75 | 54.5±11.1 | 55:20 | 53 | 25.5±21.9 |
| Elnadry, 2010 | C | 2008–2 to 2009–3 | 20 | 50.1±6.2 | 11:9 | NR | 12.5 mg increased after 2 weeks to reach 25 mg daily EBL | 12 |
| | EBL | | 20 | 51.5±8.1 | 13.7 | NR | NR |
| Ahmad et al, 2012 | C | 2008–12 to 2011–9 | 25 | NR | NR | NR | 6.25 mg/d for 1–2 weeks, increased to 12.5 mg/d EBL/2–4 weeks until eradication of varices | 12 |
| | EBL | | 25 | NR | NR | NR | 12 |
| Reiberger et al, 2013 | C | 2008–2012 | 38 | 55±11 | 28:10 | 4 | 6.25 mg/d and increased to 25 mg/d EBL/2–4 weeks until eradication of varices | 24 |
| | EBL | | 29 | 50±14 | 23.6 | 5 | 24 |

Abbreviations: C, carvedilol; EBL, endoscopic band ligation; NR, not reported; mg/d, mg/day.
The most common complication of cirrhosis—ascites, was reported in six studies. A total of 43.34% of included patients (270/623) had concomitant ascites with different severity. Moreover, six trials applied the percentage of Child–Pugh class (A/B/C) to assess the liver function and the majority of patients were found to be class B or C (69.03%). However, only one study used the form of mean (IQR) to represent the score of Child–Pugh class and the mean score was 9 (7.0–10.5) in carvedilol group and 9 (8.0–11.0) in EBL group. The mean time of follow-up ranged from 12 to 26.3 months. In general, the baseline features of included patients in carvedilol and EBL groups were basically comparable.

Treatment protocols
Carvedilol was administered orally in patients in carvedilol group (n=359) in the seven studies. Patients in four studies were given a tablet of 6.25 mg/day and then slowly increased to 12.5 mg/day if tolerated. However, in one trial, patients in the carvedilol group were given a starting dosage of 6.25 mg/day, then increased to 12.5–50 mg/day to achieve a reduction in baseline heart rate by 25% but over 55 beats/min. Another two clinical trials used 25 mg/day as long-run dose if patients could tolerate. The endpoint of EBL in all included studies was obliteration of varices except for one trial, which defined endpoint of EBL as esophageal varices being either grade I or complete obliteration. The interval of EBL in selected studies varied from 2 to 4 weeks.

Among seven included trials, five studies were associated with a low risk of bias, one study was assessed as unclear risk of bias, and one trial was evaluated as high risk of bias. Figure 2 shows the quality of the included studies as assessed by Review Manager software.

Outcome measures
Variceal bleeding
Seven studies evaluated variceal bleeding as an outcome measure. A total of 46 patients had variceal hemorrhage in the carvedilol group (12.81%), while 52 patients had it in the EBL group (14.69%). The rate of variceal bleeding ranged from 5% to 36.4% for patients with carvedilol use, and from 10% to 35.5% in patients with EBL. Four clinical trials showed that the carvedilol group had lower variceal bleeding rate than the EBL group. However, two studies demonstrated that variceal bleeding rate was lower in EBL group than in carvedilol group. Only one trial reported that variceal bleeding rate was equal in two groups. When we pooled the outcome of variceal bleeding into meta-analysis, no significant difference was noted between two groups (RR =0.86, 95% CI =0.60–1.23), as shown in Figure 3A. Moreover, statistical test indicated that the studies did not have significant heterogeneity ($I^2=11\%, P=0.35$). Therefore, the results were calculated according to the fixed-effect method. There was no evidence of publication bias through the funnel plot (Figure 4A).

However, in the seven selected trials, only one study assessed variceal rebleeding as an outcome measure. So, we performed a subgroup analysis through first and second prevention of variceal bleeding. Six studies evaluated first prevention of hemorrhage as an outcome measure. No significant difference was observed through the fixed-effect model (RR =0.81, 95% CI =0.53–1.24, $P=22\%$, Figure 3B). No evidence of publication bias was detected through the funnel plot (Figure 4B). As for the second prevention of hemorrhage, only one trial reported that 64 cases of patients with portal hypertension were randomized to this multicenter study. Variceal rebleeding occurred in 12 patients (36.4%) in the carvedilol group and 11 patients (35.5%) in the EBL group. However, this difference was also not significant according to the chi-squared test ($P=0.857$).

All-cause and bleeding-related deaths
Three trials did not report the all-cause and bleeding-related deaths due to the relatively short follow-up time (12 months). There were 49 deaths (21.30%) in the carvedilol group and 52 (23.53%) in the EBL group. There was no significant difference in the incidence of all-cause deaths between carvedilol and EBL groups (RR =0.82, 95% CI =0.44–1.53, Figure 5A). Due to the significant heterogeneity in the four studies ($I^2=66\%, P=0.03$), the random-effect model was applied. Moreover, bleeding-related deaths were also assessed as an outcome measure to compare the safety of carvedilol use vs EBL intervention. The number of patients who died from bleeding in carvedilol group (12/230) was equal to that in the EBL group (12/221). When we pooled this outcome into meta-analysis, we found that no significant difference was noted between two groups (RR =0.85, 95% CI =0.39–1.87), as shown in Figure 5B. No obvious heterogeneity ($I^2=42\%, P=0.16$) was detected through statistical tests.

Adverse events
Adverse events were confined to side effects of carvedilol or EBL, not related to the progression of chronic liver disease or symptoms of variceal bleeding. Five studies have reported the adverse events. A total of 104 adverse events (104/296) occurred in the carvedilol group, while 109 (109/296) occurred in the EBL group, as shown...
in Table 2. Although the adverse events were different in every included study, the vast majority was systematic hypotension in the carvedilol group and chest pain caused by mechanical injury in the EBL group. We tried to pool adverse events into meta-analysis and this index did not show any significant difference between two groups (RR =1.32, 95% CI =0.75–2.31, Figure 6A). Due to the obvious heterogeneity ($I^2$=81%, $P=0.0003$), we conducted
sensitivity analysis by excluding one study at a time and recalculating the pooled RRs for the remaining four studies. When we excluded Shah et al.2013, we found that the heterogeneity was significantly decreased ($I^2=54\%, P=0.09$, Figure 6B). This trial divided adverse events into serious adverse events (2 in carvedilol group and 18 in EBL group) and non-serious adverse events (48 in carvedilol group, 58 in EBL group).17 The heterogeneity was moderate and not low even after sensitivity analysis due to the diversity of adverse events reported in five clinical trials.
Discussion

Portal hypertension causes some fatal complications in patients with liver cirrhosis, such as variceal bleeding and hepatic encephalopathy. Prevention options of variceal bleeding with higher efficacy, less side effects, and lower cost are urgently needed in the clinical management of patients with portal hypertension.\(^{22,23}\) Currently, most meta-analysis was focused on comparing the efficacy of propranolol with EBL,\(^9,24,25\) or comparing the efficacy and safety of carvedilol with propranolol.\(^8\) As this newer NSBB was widely used in the prevention of variceal bleeding with fewer side effects and better tolerance in contrast to propranolol, it is significant to explore the question as follows: whether carvedilol use is more suitable for prevention of variceal bleeding than EBL intervention.

To our knowledge, this is the first meta-analysis to date comparing carvedilol use with EBL intervention for the prevention of variceal bleeding.

Table 2 Outcomes reported in the included studies

| Author, year | Group | Variceal bleeding (n/N) | All-cause mortality (n/N) | Bleeding-related mortality (n/N) | Adverse events (n/N) |
|--------------|-------|-------------------------|--------------------------|-------------------------------|---------------------|
| Abd Elrahim et al,\(^18\) 2018 | C     | 13/84                   | NR                       | NR                            | 12/84               |
| Stanley et al,\(^20\) 2014 | EBL   | 9/88                    | NR                       | NR                            | 5/84                |
| Shah et al,\(^17\) 2014 | C     | 12/33                   | NR                       | NR                            | 19/33               |
| Elndry et al,\(^13\) 2014 | EBL   | 11/31                   | NR                       | NR                            | 18/31               |
| Tripathi et al,\(^21\) 2009 | C     | 7/82                    | 20/77                    | 20/77                         | 75/86               |
| Reiberger et al,\(^16\) 2012 | EBL   | 2/25                    | NR                       | NR                            | 13/20               |
| Reiberger et al,\(^16\) 2013 | C     | 3/38                    | NR                       | NR                            | 5/20                |

Abbreviations: C, carvedilol; EBL, endoscopic band ligation; NR, not reported.
prevention of esophageal variceal bleeding. From the seven included studies, we observed that the rate of variceal bleeding was lower in carvedilol group than in EBL group. However, there was no significant difference from the forest plot (RR = 0.86, 95% CI = 0.60–1.23, \( I^2 = 11\% \)).

Carvedilol is a potent portal hypotensive agent with additional anti-\(\alpha_1\) receptor activity, which is widely applied in the management of portal hypertension, hypertension, heart failure, and ischemic heart disease. Study has shown that carvedilol reduces portal pressure not only through lowering portal-collateral blood flow (as propranolol) but also through decreasing the hepatic vascular resistance.\(^4\) The superiority of carvedilol over propranolol in reducing HVPG is associated with the \(\alpha_1\) blocking effect, which could reduce intra-hepatic resistance.\(^26\) Moreover, recent studies have demonstrated that this agent possesses antioxidant properties, exerts beneficial effects on mitochondrial function, and could decrease the resistance of insulin.\(^27\)–\(^29\) Hence, the comprehensive mechanisms of action of carvedilol make it a promising agent for the prevention of variceal bleeding in patients with cirrhosis.

Our meta-analysis did not show additional benefits of carvedilol over EBL, neither for the first prevention nor the second prevention of esophageal variceal bleeding. The fact that no significant difference is observed between the two options with regard to variceal bleeding does not necessarily indicate that the two kinds of therapy are equally effective. Carvedilol could reduce portal pressure with fewer complications, while EBL is a kind of invasive intervention without changing the potential pathophysiological mechanisms and only last for a short period of time. A retrospective study demonstrated that carvedilol was not associated with increased risk of mortality in decompensated cirrhosis patients and long-term carvedilol therapy could improve the survival of patients with cirrhosis.\(^30\) Moreover, a prospective study conducted by Kirnake et al showed that 76% patients maintained their hemodynamic response to carvedilol through intention-to-treat analysis and carvedilol treatment was associated with favorable clinical survival in patients with portal hypertension.\(^4\) Possible reasons that the benefits of carvedilol in the prevention of variceal bleeding did not translate into decreased rate of variceal bleeding are as follows: first, carvedilol is a potent portal hypotensive agent with multiple effects and these effects will be more obvious in the long run. However, most included studies have followed up for 1–2 years and three trials have followed up only for 1 year. Second, over the past decades, EBL technique has

### Table A

| Study or subgroup | Carvedilol Events Total | EBL Events Total | Weight (%) | Risk ratio M–H, random, 95% CI | Risk ratio M–H, random, 95% CI |
|------------------|------------------------|-----------------|------------|-------------------------------|-------------------------------|
| Elnady,\(^7\) 2010 | 13                     | 20              | 5          | 20                            | 17.6                          |
|                   |                        |                 |            |                               | 2.60 (1.14–5.93)              |
| Abd Elrahim et al,\(^16\) 2018 | 12                  | 84              | 5          | 84                            | 15.0                          |
|                   |                        |                 |            |                               | 2.40 (0.88–6.51)              |
| Shah et al,\(^20\) 2014 | 50                   | 82              | 75         | 86                            | 27.4                          |
|                   |                        |                 |            |                               | 0.70 (0.58–0.85)              |
| Stanley et al,\(^21\) 2014 | 19                   | 33              | 18         | 31                            | 24.5                          |
|                   |                        |                 |            |                               | 0.99 (0.65–1.51)              |
| Tripathi et al,\(^22\) 2009 | 10                   | 77              | 6          | 75                            | 15.5                          |
|                   |                        |                 |            |                               | 1.62 (0.62–4.24)              |
| Total (95% CI)   | 296                    | 296             | 100        | 1.32 (0.75–2.31)              |                               |
| Total events     | 104                    | 109             |            |                               |                               |
| Heterogeneity: \(\hat{\chi}^2=20.97, df=4 (P=0.0003); I^2=81\% \)| | | | | |
| Test for overall effect: \(Z=0.96 (P=0.34)\) | | | | | |

### Table B

| Study or subgroup | Carvedilol Events Total | EBL Events Total | Weight (%) | Risk ratio M–H, random, 95% CI | Risk ratio M–H, random, 95% CI |
|------------------|------------------------|-----------------|------------|-------------------------------|-------------------------------|
| Elnady,\(^7\) 2010 | 13                     | 20              | 5          | 20                            | 23.5                          |
|                   |                        |                 |            |                               | 2.60 (1.14–5.93)              |
| Abd Elrahim et al,\(^16\) 2018 | 12                  | 84              | 5          | 84                            | 19.1                          |
|                   |                        |                 |            |                               | 2.40 (0.88–6.51)              |
| Shah et al,\(^20\) 2014 | 50                   | 82              | 75         | 86                            | 0.0                           |
|                   |                        |                 |            |                               | 0.70 (0.58–0.85)              |
| Stanley et al,\(^21\) 2014 | 19                   | 33              | 18         | 31                            | 37.5                          |
|                   |                        |                 |            |                               | 0.99 (0.65–1.51)              |
| Tripathi et al,\(^22\) 2009 | 10                   | 77              | 6          | 75                            | 19.9                          |
|                   |                        |                 |            |                               | 1.62 (0.62–4.24)              |
| Total (95% CI)   | 214                    | 210             | 100        | 1.62 (0.92–2.85)              |                               |
| Total events     | 54                     | 34              |            |                               |                               |
| Heterogeneity: \(\hat{\chi}^2=6.56, df=3 (P=0.09); I^2=54\% \)| | | | | |
| Test for overall effect: \(Z=1.68 (P=0.09)\) | | | | | |

**Figure 6** Forest plots of adverse events.

**Notes:** (A) Five studies. (B) Four studies.

**Abbreviation:** EBL, endoscopic band ligation.
been well grasped by more and more clinicians and the higher variceal eradication rate in the EBL group may signify the lower variceal bleeding rate.

We have noted that carvedilol did not gain additional benefits in reducing adverse events as compared to EBL for the prevention of variceal bleeding. From the five included studies, we found that adverse effects occurred with similar incidence both in the carvedilol and the EBL groups. In carvedilol group, the most common serious adverse event was symptomatic hypotension. No patient in carvedilol group was reported to experience serious sodium-water retention after the use of carvedilol. However, the incidence of symptomatic hypotension due to the use of carvedilol will be decreased by starting at a very low dose (6.25 mg/day) and careful titration by gradually increasing up to 12.5 mg/day. Maharaj et al hold the view that the typical threshold for carvedilol toxicity in overdose is 50 mg. Moreover, hemodynamic monitoring is useful to reduce the incidence of symptomatic hypotension during the period of carvedilol use. Chest pain was the most common serious adverse event in EBL group, followed by esophageal ulcer. These complications in EBL group often require urgent hospitalization and could be lethal if not handled properly. However, the evaluation of adverse events in meta-analysis of included trials is often difficult due to lack of a unified definition, which is more likely to cause no significant difference of adverse events between two groups.

Several limitations still exist in our meta-analysis. First, we cannot deny the fact that the quality of some selected studies was relatively low. As carvedilol is easily differentiable from EBL operation for patients, it is hard to perform blinding for trials. Subsequently, with respect to subgroup analysis according to first and second prevention, we cannot perform a meta-analysis of second prevention due to only one available study. Third, the selected references had varying designs, including differences in dose of carvedilol, frequency of EBL, and follow-up time, which may affect the outcomes of the selected trials.

Conclusion
Our study demonstrates that no significant difference exists between carvedilol use and EBL groups in the prophylaxis of variceal bleeding. High-quality clinical trials with adequate bias control and sufficient follow-up are required in order to determine the long-term effects of both treatments.

Acknowledgment
This study was supported by grants from the National Natural Science Foundation of China (No 81602535).

Disclosure
The authors report no conflicts of interest in this work.

References
1. Tripathi D, Hayes PC. The role of carvedilol in the management of portal hypertension. Eur J Gastroenterol Hepatol. 2010;22(8):905–911.
2. García-Tsao G, Abraúldes JD, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310–335.
3. Yang L, Han GH. Revising consensus in portal hypertension: report of the Baveno V consensus workshop. J Clin Hepatol. 2011;27(2):116–118.
4. Kirmake V, Arora A, Gupta V, et al. Hemodynamic response to carvedilol is maintained for long periods and leads to better clinical outcome in cirrhosis: a prospective study. J Clin Exp Hepatol. 2016;6(3):175–185.
5. Kim HY, Jung YJ, So YH, Woo H, Kim W. Noninvasive prediction of hemodynamic response to carvedilol therapy for primary prophylaxis in cirrhotic patients with esophageal varices: a prospective study. J Hepatol. 2017;66(1):S47.
6. Tripathi D, Therapondos G, Lui HF, Stanley AJ, Hayes PC. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension. Aliment Pharmacol Ther. 2002;16(3):373–380.
7. Silkauskaitė V, Kupčiūnas J, Pranculis A, Jonaitis L, Petrenkienė V, Kupčiūnas L. Acute and 14-day hepatic venous pressure gradient response to carvedilol and nevirapine in liver cirrhosis. Medicina. 2013;49(11):73.
8. Sinagra E, Perricone G, D’Amico M, Tinè F, D’Amico G. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014;39(6):557–568.
9. Glud LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev. 2012;8:CD004544.
10. García-Pagán JC, Bosch J. Endoscopic band ligation in the treatment of portal hypertension. Nat Clin Pract Gastroenterol Hepatol. 2005;2(11):526–535.
11. Higgins JPT, Green S, editors. Cochrane Handbook for systematic reviews of interventions. Cochrane Database Syst Rev. 2008. Available from: https://www.radioterapiaitalia.it/wp-content/uploads/2017/01/cochrane-handbook-for-systematic-reviews-of-interventions.pdf. Accessed January 21, 2019.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
13. Elnady MH, Abdel-Aziz IM, Elshafiee AM, et al. Endoscopic band ligation versus carvedilol for primary prevention of bleeding esophageal varices clinical. Biochemical and Doppler Ultrasonographic Evaluation. 2010. Available from: http://www.aamj.ee.net/journals/pdf/1267. pdf. Accessed January 21, 2019.
14. Maharaj S, Seegobin K, Perez-Downes J, Bajric B, Chang S, Reddy P. Severe carvedilol toxicity without overdose – caution in cirrhosis. Clin Hypertens. 2017;23(1):25.
15. Tiniakos DG, Papatheodoridis GV. Serum markers of hepatocyte apoptosis: current terminology and predictability in clinical practice. Hepatology. 2010;51(2):717–718.
16. Reiberger T, Ulbrich G, Frlitshc A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62(11):1634–1641.
17. Shah HA, Azam Z, Rauf J, et al. Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. J Hepatol. 2014;60(4):757–764.
18. Abd Elrahim AY, Fouad R, Khairy M, et al. Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding. Hepatol Int. 2018;12(1):75–82.
19. Ahmad M, Samy E, Aal Eman A, Hosam D. Evaluation of carvedilol in prevention of first attack of variceal hemorrhage in patients with liver cirrhosis. *Afro-Egyptian Journal of Infectious and Endemic Diseases*. 2012;2(2):87–91.

20. Stanley AJ, Dickson S, Hayes PC, et al. Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. *J Hepatol*. 2014;61(5):1014–1019.

21. Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. *Hepatology*. 2009;50(3):825–833.

22. Schepke M, Drugs SM. Drugs, ligation or both for the prevention of variceal rebleeding? *Gut*. 2009;58(8):1045–1046.

23. Garcia-Pagan JC, de Gottardi A, Bosch J. Review article: the modern management of portal hypertension – primary and secondary prophylaxis of variceal bleeding in cirrhotic patients. *Aliment Pharm Ther*. 2008;28(2):178–186.

24. Li L, Yu C, Li Y. Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis. *Can J Gastroenterol*. 2011;25(3):147–155.

25. Funakoshi N, Duny Y, Valats JC. Meta-analysis: beta-blockers versus banding ligation for primary prophylaxis of esophageal variceal bleeding. *Ann Hepatol*. 2012;11(3):369–383.

26. Vorobioff J, Picabea E, Villavicencio R, et al. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients. *Hepatology*. 1987;7(4):648–653.

27. Rolo AP, Oliveira PJ, Moreno AJ, Palmeira CM. Chenodeoxycholate induction of mitochondrial permeability transition pore is associated with increased membrane fluidity and cytochrome c release: protective role of carvedilol. *Mitochondrion*. 2003;2(4):305–311.

28. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA*. 2004;292(18):2227–2236.

29. Akbas H, Ozden M, Kanko M, et al. Protective antioxidant effects of carvedilol in a rat model of ischaemia-reperfusion injury. *J Int Med Res*. 2005;33(5):528–536.

30. Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. *J Hepatol*. 2017;67(1):40–46.